RESUMEN
A new method to determine iodine in drug samples by high-resolution continuum source graphite furnace molecular absorption spectrometry (HR-CS GF MAS) has been developed. The method measures the molecular absorption of a diatomic molecule, CaI or SrI (less toxic molecule-forming reagents), at 638.904 or 677.692nm, respectively, and uses a mixture containing 5µg of Pd and 0.5µg of Mg as chemical modifier. The method employs pyrolysis temperatures of 1000 and 800°C and vaporization temperatures of 2300 and 2400°C for CaI and SrI, respectively. The optimized amounts of Ca and Sr as molecule-forming reagents are 100 and 150µg, respectively. On the basis of interference studies, even small chlorine concentrations reduce CaI and SrI absorbance significantly. The developed method was used to analyze different commercial drug samples, namely thyroid hormone pills with three different iodine amounts (15.88, 31.77, and 47.66µg) and one liquid drug with 1% m v-1 active iodine in their compositions. The results agreed with the values informed by the manufacturers (95% confidence level) regardless of whether CaI or SrI was determined. Therefore, the developed method is useful for iodine determination on the basis of CaI or SrI molecular absorption.
RESUMEN
UNLABELLED: Whole Blood Lead Level (BLL) is the main marker used to verify lead contamination. The present study explores how BLL is associated with lead concentrations in serum, saliva and house dust. Samples were collected twice from Santo Amaro, BA, Brazil, a region that was contaminated by a lead smelter in the past; a time interval of 12 months was allowed between the two collections. It is noteworthy that the following measures have recently been taken to diminish exposure of the population to lead: streets have been paved with asphalt, and educational campaigns have been launched to reduce exposure to contaminated dust. RESULTS: Compared with the first time point, all the samples collected at the second time point contained lower lead concentration (p<0.05), which suggested that the adopted measures effectively reduced exposure of the population to lead present in contaminated soil and dust. Statistically significant correlations only existed between lead in blood collected in the first year and lead in blood collected in the second year (Spearman's r=0.55; p<0.0001; n=62), and lead in house dust collected in the first year and lead in house dust collected in the second year (Spearman's r=0.5; p<0.0001; n=59). CONCLUSIONS: Results support the validity of lead determination in blood and in house dust to assess lead exposure over time. However, lead in blood and lead in dust did not correlate with lead in serum or lead in saliva.
Asunto(s)
Polvo/análisis , Contaminantes Ambientales/análisis , Plomo/análisis , Saliva/química , Suero/química , Adolescente , Brasil , Niño , Preescolar , Monitoreo del Ambiente , Contaminantes Ambientales/sangre , Femenino , Vivienda , Humanos , Plomo/sangre , MasculinoRESUMEN
The aim of this study was to see whether there would be differences in whole blood versus tibia lead concentrations over time in growing rats prenatally. Lead was given in the drinking water at 30 mg/L from the time the dams were pregnant until offspring was 28- or 60-day-old. Concentrations of lead were measured in whole blood and in tibia after 28 (28D) and 60 days (60D) in control (C) and in lead-exposed animals (Pb). Lead measurements were made by GF-AAS. There was no significant difference (P > 0.05) in the concentration of whole blood lead between Pb-28D (8.0 ± 1.1 µg/dL) and Pb-60D (7.2 ± 0.89 µg/dL), while both significantly varied (P < 0.01) from controls (0.2 µg/dL). Bone lead concentrations significantly varied between the Pb-28D (8.02 ± 1.12 µg/g) and the Pb-60D (43.3 ± 13.26 µg/g) lead-exposed groups (P < 0.01), while those exposed groups were also significantly higher (P < 0.0001) than the 28D and 60D control groups (Pb < 1 µg/g). The Pb-60D group showed a 25% decrease in tibia mass as compared to the respective control. The five times higher amount of lead found in the bone of older animals (Pb-60D versus Pb-28D), which reinforces the importance of using bone lead as an exposure biomarker.